Compare CSTM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTM | BEAM |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | France | United States |
| Employees | 12000 | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2012 | 2019 |
| Metric | CSTM | BEAM |
|---|---|---|
| Price | $25.34 | $27.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $29.00 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 05-19-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $7,335,000,000.00 | $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.46 | $22.06 |
| P/E Ratio | $22.85 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $7.33 | $13.53 |
| 52 Week High | $27.25 | $36.44 |
| Indicator | CSTM | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 47.16 |
| Support Level | $22.32 | $26.75 |
| Resistance Level | $27.25 | $28.26 |
| Average True Range (ATR) | 1.23 | 1.60 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 63.79 | 61.90 |
Constellium SE is engaged in the design and manufacture of rolled and extruded aluminium products, serving the packaging, aerospace, automotive, defence and other transportation and industry end-markets. The business is organized into three operating segments: the Packaging and Automotive Rolled Products segment which includes the production of rolled aluminium sheet products in European and North American facilities; the Aerospace and Transportation segment includes the production of rolled aluminium products and very limited volumes of extruded products in European and North American facilities; the Automotive Structures and Industry segment includes the production of extruded aluminium products and aluminium structural components.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.